Compare Stocks: PALI, HROW, XERS, and PAHC

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HROW Harrow	$40.03 +3.0%	$40.94	$28.54 ▼ $54.85	$1.50B	0.28	575,727 shs	512,054 shs
PAHC Phibro Animal Health	$34.36 +0.9%	$33.34	$28.25 ▼ $60.08	$1.39B	0.46	186,916 shs	110,782 shs
PALI Palisade Bio	$2.14 -0.5%	$1.95	$0.53 ▼ $2.86	$372.94M	1.52	1.97 million shs	1.61 million shs
XERS Xeris Biopharma	$8.60 +3.2%	$7.91	$5.25 ▼ $10.08	$1.57B	0.66	1.67 million shs	1.36 million shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HROW Harrow	0.00%	-1.01%	-10.81%	+28.26%	+9.67%
PAHC Phibro Animal Health	0.00%	+0.20%	-0.46%	-0.03%	+10.98%
PALI Palisade Bio	0.00%	+1.42%	+13.23%	+16.94%	+163.94%
XERS Xeris Biopharma	0.00%	+8.45%	-1.04%	+37.82%	+18.21%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HROW Harrow	$40.03 +3.0%	$40.94	$28.54 ▼ $54.85	$1.50B	0.28	575,727 shs	512,054 shs
PAHC Phibro Animal Health	$34.36 +0.9%	$33.34	$28.25 ▼ $60.08	$1.39B	0.46	186,916 shs	110,782 shs
PALI Palisade Bio	$2.14 -0.5%	$1.95	$0.53 ▼ $2.86	$372.94M	1.52	1.97 million shs	1.61 million shs
XERS Xeris Biopharma	$8.60 +3.2%	$7.91	$5.25 ▼ $10.08	$1.57B	0.66	1.67 million shs	1.36 million shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HROW Harrow	0.00%	-1.01%	-10.81%	+28.26%	+9.67%
PAHC Phibro Animal Health	0.00%	+0.20%	-0.46%	-0.03%	+10.98%
PALI Palisade Bio	0.00%	+1.42%	+13.23%	+16.94%	+163.94%
XERS Xeris Biopharma	0.00%	+8.45%	-1.04%	+37.82%	+18.21%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
HROW Harrow	2.55	Moderate Buy	$69.43	73.44% Upside
PAHC Phibro Animal Health	2.00	Hold	$42.50	23.69% Upside
PALI Palisade Bio	3.00	Buy	$9.00	320.56% Upside
XERS Xeris Biopharma	2.43	Hold	$10.80	25.58% Upside

Current Analyst Ratings Breakdown

Latest PALI, HROW, XERS, and PAHC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/11/2026	XERS Xeris Biopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C-) ➝ Sell (D-)
8/11/2026	HROW Harrow	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
8/11/2026	HROW Harrow	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$63.00
7/23/2026	XERS Xeris Biopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D+) ➝ Hold (C-)
7/23/2026	PALI Palisade Bio	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$8.00
7/21/2026	HROW Harrow	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$63.00
7/20/2026	HROW Harrow	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/14/2026	PALI Palisade Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/30/2026	PALI Palisade Bio	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$7.00
6/30/2026	PALI Palisade Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$2.00
6/29/2026	PALI Palisade Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 8/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
HROW Harrow	$272.30M	5.51	$0.86 per share	46.32	$1.41 per share	28.39
PAHC Phibro Animal Health	$1.30B	1.08	$3.27 per share	10.51	$7.05 per share	4.87
PALI Palisade Bio	$250K	1,491.75	N/A	N/A	$0.87 per share	2.46
XERS Xeris Biopharma	$291.85M	5.37	$0.10 per share	85.86	$0.08 per share	107.50

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
HROW Harrow	-$5.14M	-$1.00	N/A	18.45	N/A	-13.51%	-38.00%	-3.37%	N/A
PAHC Phibro Animal Health	$48.26M	$2.33	14.75	10.32	0.49	6.35%	37.14%	8.57%	8/26/2026 (Estimated)
PALI Palisade Bio	-$16.78M	-$1.01	N/A	N/A	N/A	N/A	-33.47%	-31.79%	N/A
XERS Xeris Biopharma	$550K	-$0.11	N/A	28.67	N/A	-5.12%	338.21%	3.50%	N/A

Latest PALI, HROW, XERS, and PAHC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/26/2026	Q4 2026	PAHC Phibro Animal Health	$0.72	N/A	N/A	N/A	$381.18 million	N/A
8/10/2026	Q2 2026	HROW Harrow	-$0.1788	-$0.46	-$0.2813	-$0.46	$70.35 million	$70.66 million
8/10/2026	Q2 2026	PALI Palisade Bio	-$0.0522	-$0.05	+$0.0022	-$0.05	$0.50 million	$0.50 million
8/6/2026	Q2 2026	XERS Xeris Biopharma	$0.0121	-$0.18	-$0.1921	-$0.18	$90.13 million	$92.10 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
HROW Harrow	N/A	N/A	N/A	N/A	N/A
PAHC Phibro Animal Health	$0.48	1.40%	N/A	20.60%	N/A
PALI Palisade Bio	N/A	N/A	N/A	N/A	N/A
XERS Xeris Biopharma	N/A	N/A	N/A	N/A	N/A

Latest PALI, HROW, XERS, and PAHC Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/28/2026	PAHC Phibro Animal Health	quarterly	$0.12	1.32%	9/2/2026	9/2/2026	9/23/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
HROW Harrow	19.70	2.24	2.08
PAHC Phibro Animal Health	1.97	3.17	1.26
PALI Palisade Bio	N/A	24.26	24.26
XERS Xeris Biopharma	17.00	1.45	1.02

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
HROW Harrow	72.76%
PAHC Phibro Animal Health	99.34%
PALI Palisade Bio	11.79%
XERS Xeris Biopharma	42.75%

Insider Ownership

Company	Insider Ownership
HROW Harrow	12.80%
PAHC Phibro Animal Health	50.13%
PALI Palisade Bio	0.07%
XERS Xeris Biopharma	4.35%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
HROW Harrow	180	37.49 million	32.69 million	Optionable
PAHC Phibro Animal Health	2,475	40.56 million	20.23 million	Optionable
PALI Palisade Bio	10	174.27 million	174.15 million	Not Optionable
XERS Xeris Biopharma	290	182.32 million	174.39 million	Optionable

PALI, HROW, XERS, and PAHC Headlines

Recent News About These Companies

Why Xeris Biopharma Holdings (XERS) Is Up 8.4% After Tightening 2026 Revenue Guidance And Advancing XP-8121

3 hours ago | finance.yahoo.com

Walleye Capital LLC Invests $4.84 Million in Xeris Biopharma Holdings, Inc. $XERS

August 15 at 6:32 AM | marketbeat.com

Xeris (XERS) Q2 2026 Earnings Call Transcript

August 13 at 2:36 PM | finance.yahoo.com

Insider Selling: Xeris Biopharma (NASDAQ:XERS) Insider Sells 5,000 Shares of Stock

August 13 at 7:51 AM | insidertrades.com

Xeris Biopharma FY2026 EPS Estimate Lowered by HC Wainwright

August 13 at 2:13 AM | americanbankingnews.com

Xeris Biopharma (NASDAQ:XERS) Insider Sells $42,500.00 in Stock

August 12, 2026 | marketbeat.com

HC Wainwright Comments on Xeris Biopharma FY2026 Earnings

August 11, 2026 | marketbeat.com

Janus Henderson Group PLC Boosts Stock Holdings in Xeris Biopharma Holdings, Inc. $XERS

August 10, 2026 | marketbeat.com

Renaissance Technologies LLC Cuts Stock Position in Xeris Biopharma Holdings, Inc. $XERS

August 10, 2026 | marketbeat.com

Xeris Biopharma Q3 EPS Forecast Reduced by HC Wainwright

August 10, 2026 | americanbankingnews.com

HC Wainwright Expects Weaker Earnings for Xeris Biopharma

August 10, 2026 | marketbeat.com

Sei Investments Co. Has $3.36 Million Stake in Xeris Biopharma Holdings, Inc. $XERS

August 8, 2026 | marketbeat.com

Xeris Biopharma (NASDAQ:XERS) Shares Gap Down on Disappointing Earnings

August 8, 2026 | americanbankingnews.com

Xeris Biopharma (NASDAQ:XERS) Downgraded by Wall Street Zen to "Buy"

August 8, 2026 | americanbankingnews.com

Xeris Biopharma (NASDAQ:XERS) Downgraded to "Buy" Rating by Wall Street Zen

August 8, 2026 | marketbeat.com

Xeris Biopharma Q2 Earnings Call Highlights

August 7, 2026 | marketbeat.com

Xeris Biopharma (NASDAQ:XERS) Issues Earnings Results, Misses Expectations By $0.19 EPS

August 6, 2026 | marketbeat.com

Xeris forecasts $385M-$390M 2026 revenue as Recorlev expands and XP-8121 phase III start targets year end

August 6, 2026 | seekingalpha.com

Xeris Biopharma Holdings, Inc. (XERS) Q2 2026 Earnings Call Transcript

August 6, 2026 | seekingalpha.com

Xeris Biopharma (NASDAQ:XERS) Shares Gap Down Following Weak Earnings

August 6, 2026 | marketbeat.com

Compared to Estimates, Xeris Biopharma (XERS) Q2 Earnings: A Look at Key Metrics

August 6, 2026 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PALI, HROW, XERS, and PAHC Company Descriptions

Harrow NASDAQ:HROW

$40.03 +1.16 (+2.98%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$40.44 +0.41 (+1.01%)

As of 08/14/2026 07:56 PM Eastern

Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.

Phibro Animal Health NASDAQ:PAHC

$34.36 +0.30 (+0.88%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$34.32 -0.04 (-0.12%)

As of 08/14/2026 05:55 PM Eastern

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.

Palisade Bio NASDAQ:PALI

$2.14 -0.01 (-0.47%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$2.11 -0.03 (-1.40%)

As of 08/14/2026 07:37 PM Eastern

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California.

Xeris Biopharma NASDAQ:XERS

$8.60 +0.27 (+3.24%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$8.64 +0.04 (+0.41%)

As of 08/14/2026 07:34 PM Eastern

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PALI, HROW, XERS, and PAHC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PALI, HROW, XERS, and PAHC Earnings

Compare Dividends

Latest PALI, HROW, XERS, and PAHC Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PALI, HROW, XERS, and PAHC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PALI, HROW, XERS, and PAHC Company Descriptions

Harrow NASDAQ:HROW

Phibro Animal Health NASDAQ:PAHC

Palisade Bio NASDAQ:PALI

Xeris Biopharma NASDAQ:XERS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PALI, HROW, XERS, and PAHC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PALI, HROW, XERS, and PAHC Earnings

Compare Dividends

Latest PALI, HROW, XERS, and PAHC Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PALI, HROW, XERS, and PAHC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PALI, HROW, XERS, and PAHC Company Descriptions

Harrow NASDAQ:HROW

Phibro Animal Health NASDAQ:PAHC

Palisade Bio NASDAQ:PALI

Xeris Biopharma NASDAQ:XERS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools